Avita Medical, Inc. · NASDAQ:RCEL

Avita Medical — Investor Presentation (May 2022)

41 slides from Avita Medical's investor presentation, May 12, 2022

  1. Slide 1: AVITA Medical Corporate Presentation May 2022

    For personal use only 0D\ 1$6'$45&(/ $6;$9+ ‹&RS\ULJKW$9,7$0HGLFDO$OO5LJKWV5HVHUYHG

  2. Slide 2: Legal Disclaimers

    /HJDO'LVFODLPHUV For personal use only &HUWDLQVWDWHPHQWVLQWKLVSUHVHQWDWLRQDQGWKHDFFRPSDQ\LQJ RUDOFRPPHQWDU\ DUH³IRUZDUGORRNLQJ VWDWHPHQWV´ ZLWKLQWKHPHDQLQJ RIWKH3ULYDWH6HFXULWLHV/LWLJDWLRQ 5HIRUP$FWRI$OOVWDWHPHQWV RWKHUWKDQVWDWHPHQWV RIKLVWRULFDOIDFWVFRQWDLQHGLQWKLVSUHVHQWDWLRQ LQFOXGLQJVWDWHP HQWVU

  3. Slide 3: Transforming Lives with Skin Regeneration

    7UDQVIRUPLQJ/LYHV ZLWK6NLQ5HJHQHUDWLRQ For personal use only ‡ 5(&(//Š 6\VWHP)'$DSSURYHGIRUWKHWUHDWPHQWRIDFXWHWKHUPDO EXUQV o 3URSULHWDU\6SUD\2Q 6NLQ70 RIIHUVOLIHFKDQJLQJ EHQHILWV o 3RLQWRIFDUHWHFKQRORJ\ WKDWLVVDIH HIIHFWLYH o 3XEOLVKHG KHDOWK HFRQRPLFPRGHO GHPRQVWUDWLQJ KRVSLWDOFRVWVDYLQJV ‡ 'HHSVF

  4. Slide 4: One Platform, Endless Possibilities

    2QH3ODWIRUP(QGOHVV3RVVLELOLWLHV For personal use only 5(&(//HQDEOHV 9LWLOLJR 5(&(//GHOLYHUVKHDOWK\ VNLQFHOOV UHJHQHUDWLRQRI KHDOWK\VNLQ 7UDXPD $XWRORJRXVVNLQFHOOV DUHVSUD\HGRQSDWLHQW %XUQV6FDOGV &KURQLF:RXQGV 6FDU5HYLVLRQ +HDOWK\ VNLQSURFHVVHG XVLQJWKH5(&(//6\VWHP P ,QIHFWLRXV'LVHDVH 3DWFKRIKHDOWK\

  5. Slide 5: Value Creation

    9DOXH&UHDWLRQ For personal use only 5HFHQW.H\$FFRPSOLVKPHQWV 3URMHFWHG.H\0LOHVWRQHV ‡ )LUVW4XDUWHU 5HYHQXH *URZWK RI<R< ‡ /DXQFK RI1HZ³(DVHRI8VH´5(&(//'HYLFH 4¶ ‡ )'$$SSURYDO RI1HZ³(DVHRI8VH´5(&(//'HYLFH ‡ )'$0HHWLQJ 5HJDUGLQJ ,1' (QDEOLQJ 6WXGLHV +¶ ‡ 9LWLOLJR3LYRWDO7ULDO(QUROOPHQW &RPSOHWH (% 5HMX

  6. Slide 6: Development Pipeline and Growth Potential

    For personal use only 'HYHORSPHQW3LSHOLQHDQG*URZWK3RWHQWLDO

  7. Slide 7: Focused Pipeline with Strong Growth Potential

    )RFXVHG3LSHOLQH ZLWK6WURQJ*URZWK3RWHQWLDO For personal use only ,1',&$7,21 ',6&29(5< )($6,%,/,7< 3,927$/ $33529$/ /$81&+ 5HJHQHUDWLYH7KHUDSHXWLFV ± :RXQGV 'HUPDWRORJ\ &XUUHQW 3ODWIRUP $FXWH7KHUPDO%XUQV 86 5(&(// Š -DSDQ 9LWLOLJR 86 (152//0(17&203/(7( 7 6RIW7LVVXH5HFRQVWUXFWLRQ 86 (152//0(17&203/(7(

  8. Slide 8: Market Opportunity of Pipeline Exceeds Billion

    0DUNHW2SSRUWXQLW\RI3LSHOLQH ([FHHGV%LOOLRQ For personal use only (;,67,1* 3/$7)250 1(:3/$7)2506&(//%$6('*(1(7+(5$3< a%2SSRUWXQLW\ a%2SSRUWXQLW\ % % %XUQV 9LWLOLJR % % % % 5HMXYHQDWLRQ 6NLQFHOOVDUH (SLGHUPRO\VLV 6RIW7LVVXH JHQHWLFDOO\ PRGLILHG %XOORVD !%LOOLRQLQ&RPELQHG727$/$''5(66$%/(0$5.(7

  9. Slide 9: Current Platform Efficacy is Well Demonstrated

    &XUUHQW3ODWIRUP(IILFDF\LV:HOO'HPRQVWUDWHG For personal use only 352'8&7,6:(//678',(' 3DWLHQWV 1XPEHU RI3XEOLFDWLRQV LQ3XEOLVKHG 6WXGLHV 3UHVHQWDWLRQV $&87( :281'6 +LJKO\ 'HULVNHG (Including Thermal Burns) 3LSHOLQH ZLWK '()(&76 !3DWLHQWV 9,7,/,*2 7UHDWHG*OREDOO\ &+521,& :281'6 $&RPPRQ*RDO)XOO6NLQ5HVW

  10. Slide 10: Thermal Burns US Target Market Expanded to Include Small Burns and Outpatient

    7KHUPDO%XUQV867DUJHW0DUNHW([SDQGHGWR ,QFOXGH6PDOO%XUQVDQG2XWSDWLHQW For personal use only 3DWLHQW)XQQHODQG$GGUHVVDEOH0DUNHW 865(&(//&RPPHUFLDO 6DOHV6LQFH$SSURYDO a. 7RWDO$QQXDO%XUQVLQWKH86 3 $7,( 1 76 !0LOOLRQ7$0 a. 6HYHUH%XUQV DVGHILQHGDVEXUQV!%RG\ 6XUIDFH$UHDWKDWPD\UHTXLUHJUDIWLQJ 3 $7,( 1 76 ($ 0

  11. Slide 11: New C-Code Provides Additional Payment in the Outpatient Setting

    1HZ&&RGH3URYLGHV$GGLWLRQDO 3D\PHQWLQWKH2XWSDWLHQW6HWWLQJ For personal use only 7KH &HQWHUV IRU 0HGLFDUHDQG0HGLFDLG & 6HUYLFHV &06 FUHDWHG $XWRJUDIW VXVSHQVLRQLQFOXGLQJ FHOO DQHZWHFKQRORJ\ SURFHVVLQJDQGDSSOLFDWLRQ DQG DOO 7UDQVLWLRQDO 3DVV V\VWHPFRPSRQHQWV 7KLVLVD0HGLFDUH 7KURXJK 737 3D\PHQW VSHFLILF

  12. Slide 12: New Ease-of-Use Device Now FDA Approved

    1HZ(DVHRI8VH'HYLFH 1RZ)'$$SSURYHG For personal use only 1HZ'HYLFH 5HGXFHG 6LPSOLILHG ,PSURYHG QXPEHURIVWHSV 3URFHVV 8VDELOLW\ RIVXUYH\HG XVHUVRIWKH 5(&(//6\VWHP EHOLHYHLWZLOO UHGXFHWKHLU ZRUNORDGDOORZ WKHPWRSHUIRUP RWKHUGXWLHV 2QO\6HWRI+DQGV5HTXLUHGLQWKH6WHULOH)LHOG6WHSV5HGXFHG%\ 0DUNHW5HVHDUFK0DUFK

  13. Slide 13: FDA Approval in Pediatric Full Thickness, Larger Burns

    )'$$SSURYDO LQ3HGLDWULF)XOO7KLFNQHVV /DUJHU%XUQV For personal use only )(:(5352&('85(6 5(48,5(' )25'(),1,7,9( &/2685( 96 &219(17,21$/ $872*5$)7 1%5&RQWURO 5(&(// 180%(5 2) 75($70(176 180%(5 2) 75($70(176 3HGLDWULF3DWLHQWV $GXOWVZLWK!7%6$ aRIDOOEXUQV IHZHUPHDQSURFHGXUHVZLWK5(&(// 1 p < 0.0001 IHZHUPH

  14. Slide 14: Approval of Burns Received in Japan

    $SSURYDORI%XUQV5HFHLYHG LQ-DSDQ For personal use only %$&.*5281' 3$7,(17 )811(/ %8516 $''5(66$%/( 0$5.(7 $9,7$&RPPHUFLDO3DUWQHU &26027(&DQ0&RPSDQ\ a ,QFLGHQFHRI%XUQV1HHGLQJ 0HGLFDO7UHDWPHQWLQ-DSDQ 3 $7,( 1 76 ,1',&$7,21%XUQV a 6HYHUH%XUQV GHILQHGDVKRVSLWDO DGPLVVLRQVRIEXUQVWKDWPD\ 3 $7,( 1 76 UHTXLU

  15. Slide 15: Vitiligo: High Unmet Need, No FDA Approved Products

    9LWLOLJR +LJK8QPHW1HHG1R)'$$SSURYHG3URGXFWV For personal use only 6,*1,),&$17810(71((' 23325781,7<(67,0$7,21 727$/ 0$5 . ( 7 8SWRRIWKH 0 3UHYDOHQFHRI9LWLOLJR LQWKH8QLWHG6WDWHV SRSXODWLRQ DIIHFWHG U D Q J H P L O O L R Q 727$/ $' ' 5 ( 6 6 $% / ( 0$5 . ( 7 7$0 0 %LOOLRQ 1R)'$DSSURYHGPHGLFDOWUHDWPHQWV

  16. Slide 16: Vitiligo Study Enrollment Complete

    9LWLOLJR 6WXG\(QUROOPHQW&RPSOHWH For personal use only %OLQGHG 5DQGRPL]HG 6WXG\ (YDOXDWLQJ 5(&(//IRU5HSLJPHQWDWLRQ RI6WDEOH9LWLOLJR 5(&(//Š 9LWLOLJR6WXG\ 3DWLHQWIURPD3ULRU6WXG\DW0217+6 5(&(//WUHDWHGDUHDZDVUHSLJPHQWHG 1XPEHURI6XEMHFWV 5(&(// WUHDWHG (152//0(17&203/(7( 1HJDWLYH &RQWURO .RPHQ/9ULMPDQ &

  17. Slide 17: RECELL Case: Repigmentation of the Nipple Areola Complex

    5(&(//&DVH5HSLJPHQWDWLRQ RIWKH1LSSOH$UHROD &RPSOH[ For personal use only %HIRUH5(&(//Š PRQWKV$IWHU5(&(// Š ‡ \HDUROGIHPDOHZLWKYLWLOLJR ‡ 'RQRUVNLQZDVKDUYHVWHGIURPDGMDFHQWXQDIIHFWHGDUHDV ‡ 'HSLJPHQWHGHSLGHUPLVZDVUHPRYHGXVLQJGHUPDEUDVLRQ ‡ 7KHFHOOXODUVXVSHQVLRQZDVWKHQVSUD\HGRQERWKWKHUHFLSLHQWDQGGRQRUD

  18. Slide 18: Soft Tissue Repair Will Expand the Burns Business to Encompass All Acute Wounds

    6RIW7LVVXH5HSDLU:LOO([SDQGWKH%XUQV%XVLQHVV WR(QFRPSDVV$OO$FXWH:RXQGV For personal use only )HPDOH SUHJQDQW \HDUROGZKR 23325781,7<(67,0$7,21 VXIIHUHGIURP DGHJORYLQJ ,QMXU\ 727$/ 0$5 . ( 7 2SHQZRXQGV !0 SUHVHQWHGDWWKH (PHUJHQF\ SDWLHQWV 'HSDUWPHQW 3267'(%5,'(0(172),1-85< 727$/ $' ' 5 ( 6 6 $% / ( 0$5

  19. Slide 19: Early Completion of Soft Tissue Reconstruction Trial

    (DUO\&RPSOHWLRQ RI6RIW7LVVXH5HFRQVWUXFWLRQ7ULDO For personal use only &OLQLFDOWULDOGHPRQVWUDWHV XVHRIOHVVGRQRUVNLQZLWKRXW FRPSURPLVLQJ KHDOLQJ RXWFRPHV UHODWLYHWRFRQYHQWLRQDO DXWRJUDIWLQJ 3DWLHQWWUHDWHGIRUQHFURWL]LQJ IDVFLLWLV 5(&(//Š 6RIW7LVVXH6WXG\ 1 1XPEHURI6LWHV(QUROOLQJ 1XPEHURI6XEMHFWV (152//0

  20. Slide 20: Soft Tissue Synergies with Current Commercial Burn Focus

    6RIW7LVVXH6\QHUJLHV ZLWK&XUUHQW&RPPHUFLDO %XUQ)RFXV For personal use only ([SDQGHG$FXWH:RXQGV6DOHV7HDP:LOO 7DUJHWD7RWDORI &HQWHUV 5HLPEXUVHPHQWLQ3ODFH 5 $ $EOHWROHYHUDJHH[LVWLQJ&37 2XWSDWLHQW &&RGH & aRI%XUQ %XUQ &HQWHUVDUHDOVR HDOV VR 6DPH7UHDWPHQW3URWRFROWR%XUQV /HYHO/HYHO HYHOO %XUQ &RQVLVWHQWWUH

  21. Slide 21: RECELL in Genetic Skin Defects and Rejuvenation

    5(&(//LQ*HQHWLF6NLQ'HIHFWVDQG5HMXYHQDWLRQ For personal use only &855(173/$7)250 )8785(3/$7)250 7UHDWPHQWXVLQJ5(&(//IRUKDUYHVWLQJDQGGLUHFWUHLQWURGXFWLRQRIWKH 5(&(//DVDSODWIRUPIRUWUHDWPHQWXVLQJWKHSDWLHQW¶V SDWLHQW¶VRZQKHDOWK\VNLQFHOOV FRUUHFWHGVNLQFHOOV $XWRORJRXV VNLQ FHOOV (QKDQFHGDXWRORJRXV VNLQ FH

  22. Slide 22: Cell and Gene Therapy Development Activity

    &HOODQG*HQH7KHUDS\'HYHORSPHQW$FWLYLW\ For personal use only 3URRIRI&RQFHSW 3URJUDP2EMHFWLYH )'$,QWHUDFWLRQ )285 2SWLPL]H6SUD\2Q6NLQΠ&HOOVZLWKmodified VNLQ .(< FHOOVDQGHVWDEOLVK,1' 67(36 ,1'HQDEOLQJ6WXGLHV UHDGLQHVV )LUVWLQKXPDQ ,1'

  23. Slide 23: Sizeable Market Opportunity Estimated in EB Given Orphan Pricing Potential

    6L]HDEOH 0DUNHW2SSRUWXQLW\(VWLPDWHG LQ(%*LYHQ2USKDQ 3ULFLQJ3RWHQWLDO For personal use only 23325781,7<(67,0$7,21 327(17,$/ &203(7,7,9( $'9$17$*(6 6XVSHQVLRQLVSRWHQWLDOO\PRUHFRVWHIIHFWLYHWR 863UHYDOHQFHRI (SLGHUPRO\VLV%XOORVD JHQHUDWHWUDQVSRUWDQGDSSO\YVFXOWXUHGVKHHW JUDIWV SHRSOH 863UHYDOHQFHRI '\VWU

  24. Slide 24: Skin Regeneration from Corrected Autologous Skin Cell Suspension

    6NLQ5HJHQHUDWLRQ IURP&RUUHFWHG$XWRORJRXV6NLQ&HOO6XVSHQVLRQ For personal use only 6XFFHVVIXOUHYHUVHGLIIHUHQWLDWLRQ LQGXFHG SOXULSRWHQF\ DQGJHQHFRUUHFWLRQRI In Vivo (YDOXDWLRQRI*HQHFRUUHFWHG6NLQ&HOOV 5HFHVVLYH'\VWURSKLF(SLGHUPRO\VLV%XOORVD ,PPXQRFRPSURPLVHG 5'(% 6NLQ&HOOV PRXVHPRGHO &RUUHFWLRQRI5'(% 6

  25. Slide 25: Exploring Cell-Based Gene Therapy for Epidermolysis Bullosa

    ([SORULQJ&HOO%DVHG *HQH7KHUDS\IRU(SLGHUPRO\VLV %XOORVD For personal use only 7+(&+$//(1*( 7+(23325781,7< '(%,/,7$7,1* 6NLQIUDJLOLW\ &85$7,9(7HFKQRORJ\IRUSUHFLVHFRUUHFWLRQRI GLVDELOLW\FDQFHU JHQHWLFGHIHFW EDQNLQJIRUIXWXUHXVH YVDPHOLRUDWLQJ V\PSWRPV +,*+810(7 1((' 1R)'$DSSURYHG ()),&,(176XVSHQVLRQEDVH

  26. Slide 26: Reverse Aging of Skin Cells Derived Using the RECELL Device

    5HYHUVH$JLQJRI6NLQ&HOOV 'HULYHG XVLQJWKH5(&(//'HYLFH For personal use only 6XFFHVVIXOGHOLYHU\RIP51$K7(57 H[SUHVVLRQLQ 6NLQ&HOOV'HULYHGIURP5(&(// In Vivo (YDOXDWLRQRIP51$K7(570RGLILHG6NLQ&HOOV 3RLQWRI&DUH ,PPXQRFRPSURPLVHG K7(57PRGLILFDWLRQ PRXVHPRGHO 6NLQFHOOV KDUYHVWHGIURP &(//'HYLFH 5(&(//'HYLFH 7

  27. Slide 27: Exploring Novel RNA-Based Approach for Rejuvenation

    ([SORULQJ 1RYHO 51$%DVHG$SSURDFKIRU5HMXYHQDWLRQ For personal use only 3DWLHQW)XQQHODQG $GGUHVVDEOH0DUNHW a0 3 ( 23 / ( <U 3HRSOH :KR8QGHUZHQW )DFLDO $HVWKHWLF3URFHGXUHV $LPHGDW ,PSURYLQJ 6NLQ7LJKWQHVV 7H[WXUH (YHQQHVV LQ6NLQ7RQH ‡ 3DWHQWHG51$WHFKQRORJ\IRUGHOLYHU\RI U\ RI ‡ 3DWHQWHGDQGSURSULHWDU\6SUD

  28. Slide 28: Corporate

    For personal use only &RUSRUDWH

  29. Slide 29: Financial Overview

    )LQDQFLDO 2YHUYLHZ For personal use only 8QDXGLWHG0RQWKV 8QDXGLWHG0RQWKV 0RQWKV(QGHG-XQH (QGHG'HFHPEHU (QGHG0DUFK (USD in $000s) &RPPHUFLDO6DOHV %$5'$6DOHV 7RWDO5HYHQXH *URVV3URILW %$5'$,QFRPH &DVK &DVK (TXLYDOHQWV 0DUNHWDEOH 6HFXULWLHV $QDO\VWV 1$6'$4 WLFNHU $6;WLFNHU ‡ 0DWW2 %ULHQ 3LSHU 86 ‡ %URRN

  30. Slide 30: A Global Total of Granted Patents and Pending Applications

    $*OREDO7RWDORI*UDQWHG3DWHQWV 3HQGLQJ$SSOLFDWLRQV For personal use only (;3$1',1*3257)2/,2726833257&855(17$1' 52%8673527(&7,21$&52663$7(17)$0,/,(6 )8785(,1',&$7,216 &HOO6XVSHQVLRQ &RPPHUFLDO5(&(//GHYLFHFRPSRVLWLRQRI 1H[W*HQHUDWLRQ5(&(//GHYLFHVWRLPSURYHHDVHRI 3UHSDUDWLRQ7HFKQLTXH DQG8VH PDWWHUDQGDVVRF

  31. Slide 31: AVITA Leadership Team

    $9,7$/HDGHUVKLS7HDP For personal use only 'U0LFKDHO ' 0L K O 6 63HUU\ 3 0LFKDHO +ROGHU (ULQ/LEHUWR ( L /LE W $QGUHZ 4XLFN $QGUHZ4XLFN .DWK\0F*HH . WK 0 * 'RQQD6KLURPD ' 6KL &(2 &)2 &&2 &72 &22 *HQHUDO&RXQVHO >30 years experience >30 years experience >20 years experience >25 years experience >25 year

  32. Slide 32: Value Creation

    9DOXH&UHDWLRQ For personal use only 5HFHQW.H\$FFRPSOLVKPHQWV 3URMHFWHG.H\0LOHVWRQHV ‡ )LUVW4XDUWHU 5HYHQXH *URZWK RI<R< ‡ /DXQFK RI1HZ³(DVHRI8VH´5(&(//'HYLFH 4¶ ‡ )'$$SSURYDO RI1HZ³(DVHRI8VH´5(&(//'HYLFH ‡ )'$0HHWLQJ 5HJDUGLQJ ,1' (QDEOLQJ 6WXGLHV +¶ ‡ 9LWLOLJR3LYRWDO7ULDO(QUROOPHQW &RPSOHWH (% 5HMX

  33. Slide 33: Risk Factors and Disclosures

    5LVN)DFWRUVDQG'LVFORVXUHV For personal use only ‡ 7KHUHDUHQXPHURXVULVNIDFWRUVLQYROYHG ZLWKWKH&RPSDQ\¶VEXVLQHVV6RPHRIWKHVHULVNVFDQEHPLWLJDWHGE\WKHXVHRIVDIHJXDUGVDQGDSSURSULDWHV\VWHPVDQGFRQWUROVEXWVRPH DUHRXWVLGHWKHFRQWURORIWKH&RPSDQ\DQGFDQQRWEHPLWLJDWHG$FFRUGLQJO\DQLQYHVWPHQWLQWKH&RPSDQ\FDUULHVQRJXDU

  34. Slide 34: Important Safety Information

    ,PSRUWDQW6DIHW\,QIRUPDWLRQ For personal use only ‡ ,1',&$7,216 )2586(7KH5(&(//Š$XWRORJRXV&HOO+DUYHVWLQJ'HYLFHLVLQGLFDWHGIRUWKHWUHDWPHQW RIDFXWHWKHUPDO EXUQZRXQG V 7KH5(&(//GHYLFHLVXVHGE\ DQDSSURSULDWHO\OLFHQVHGKHDOWKFDUH SURIHVVLRQDODWWKHSDWLHQW¶VSRLQWRIFDUHWRSUHSDUHDXWRORJRXV5(6Š5HJHQHUDWLYH(SLGHUP

  35. Slide 35: Revolutionary treatment using a patient's own skin for life-changing outcomes

    For personal use only 5HYROXWLRQDU\ WUHDWPHQWXVLQJD SDWLHQW¶VRZQVNLQ IRUOLIHFKDQJLQJ RXWFRPHV =HGWUHDWHGZLWKWKH5(&(//Š 6\VWHP 1$6'$4&05&(/ $6;$9+ ‹ $OOULJKWVUHVHUYHG ,Q WKH86 5(&(// LVDSSURYHG IRUDFXWHWKHUPDO EXUQV8VHRI5(&(// LQRWKHULQGLFDWLRQV LVHLWKHU OLPLWHG E\8QLWHG 6WDWHV ODZ WRLQYHVWLJDWLRQDO

  36. Slide 36: RECELL Process for Autologous Cell Harvesting and Application

    5(&(//3URFHVV)RU$XWRORJRXV&HOO+DUYHVWLQJ DQG$SSOLFDWLRQ For personal use only +$59(67 ,1&8%$7( ',6$**5(*$7( 5,16( ),/7(5 $33/<

  37. Slide 37: RECELL SprayOn Skin

    5(&(//6SUD\2Q6NLQ70 7UHDWVFP RI6NLQIURPDFP %LRSV\ For personal use only $872/2*286 &203/(7( &HOO+DUYHVWLQJ'HYLFHWKDWGHOLYHUV )XOOUDQJHRIVNLQFHOOW\SHVZLWK 6SUD\2Q 6NLQ&HOOVZLWKLQ UHSLJPHQWDWLRQ PLQXWHV DWWKHSRLQWRIFDUH 63/,77+,&.1(666.,1*5$)7 '21256,7( $&7,9$7(' 6$)( ())(&7,9( )UHVK QRQFXOWXUHG FHOOV

  38. Slide 38: 1st Premarket Approval Treatment in Burns in 30 Years

    VW3UHPDUNHW$SSURYDO7UHDWPHQWLQ%XUQVLQ<HDUV For personal use only 'XDO PXOWLFHQWHU UDQGRPL]HG FRQWUROOHG SUHPDUNHW DSSURYDOVWXGLHV 3LYRWDO7ULDO 3DWLHQWV 3LYRWDO7ULDO 3DWLHQWV 5(&(// DORQH YHUVXV6R& 676* LQ 5(&(// ZLWKZLGHO\H[SDQGHGJUDIW YHUVXV676*LQ 6HFRQG'HJUHH%XUQV 7KLUG'HJUHH%XUQV 3XEOLVKHGLQ-%&5

  39. Slide 39: RECELL Free-Edge Advantage

    5(&(// ³)UHH(GJH´$GYDQWDJH For personal use only +HDOLQJ3URFHVVZLWKRXW 5(&(// +HDOLQJ3URFHVVZLWK 5(&(// )UHHHGJHOLPLWVVLJQDOLQJ 6SUD\2Q6NLQ&HOOVVLJQDO WRZRXQGERXQGDU\ IURPZLWKLQWKHZRXQG LHRXWVLGHĺLQ LHLQVLGHĺRXW

  40. Slide 40: Skin Injury Framework

    6NLQ,QMXU\)UDPHZRUN For personal use only 7$5*(7,1-85< 6XSHUILFLDO:RXQG 6XSHUILFLDO3DUWLDO 'HHS3DUWLDO )XOO7KLFNQHVV 7KLFNQHVV:RXQG 7KLFNQHVV:RXQG :RXQG :RXQG'HSWK VW GHJUHH QG GHJUHH QG GHJUHH UG GHJUHH :RXQG6L]H 7RWDO%RG\6XUIDFH$UHD 7%6$ $IIHFWHG $GRSWLRQ7UDMHFWRU\ 6PDOO3DUWLDO7KLFNQHVVĸ5HVXOWV([S

  41. Slide 41: Published Health Economic Model Demonstrates Patient and Health Care System Benefits

    3XEOLVKHG+HDOWK(FRQRPLF0RGHO 'HPRQVWUDWHV3DWLHQWDQG+HDOWK&DUH6\VWHP%HQHILWV For personal use only 5(&(//VDYHVWKHKRVSLWDO PRQH\ LQLQSDWLHQW VFHQDULRVZKHUHWKHEXUQ LV 7RWDO%RG\6XUIDFH$UHD 7%6$ RUJUHDWHU 7UDQVIRUPLQJ&DUH &DQUHGXFHFRVWVDQGDFFHOHUDWHUHFRYHU\E\GHFUHDVLQJ WKHQXPEHURISDLQIXOSURFHGXUHVDQGOHQJ

AVITA Medical — Investor Presentation (May 2022) on 6ix